Table 1.

Distribution of GFI1^36N in AML patients and healthy control patients

Population	AA	GA	GG	Frequency allele A	OR	P*	95% CI
German and Dutch patients and control patients
Patients	1	195	1610	0.054 ± 0.005	1.6	< 8 × 10−5	1.3-2
Control patients	1	118	1572	0.035 ± 0.003
Patients by location
Germany patients	1	134	1129	0.053 ± 0.004	1.6	< 2 × 10−3	1.2-2
Germany control patients	1	87	1162	0.035 ± 0.004
The Netherlands patients	0	61	481	0.056 ± 0.007	1.6	.02	1.1-2.6
The Netherlands control patients	0	31	410	0.035 ± 0.006
According to smoking status†
Smokers AML	0	9	39	0.09 ± 0.028	3.4	.04	1.1-11.8
Smokers control patients	0	4	59	0.03 ± 0.015
Nonsmokers AML	0	13	41	0.12 ± 0.016	4.3	.003	1.5-12.2
Nonsmokers control patients	0	6	82	0.03 ± 0.013

Allele frequencies for the GFI1^36N variant among white AML patients and control patients in Germany and in The Netherlands. GFI1^36N was enriched 1.6-fold in AML patients (P < 8 × 10⁻⁵) compared with the control population, which was confirmed after adjusting for age and sex.

AML indicates acute myeloid leukemia; CI, confidence interval; GFI1, Growth Factor Independence 1; and OR, odds ratio.

^*The Hardy-Weinberg equilibrium was tested and fit expectation with the exception that the frequency of genotype AA was lower than expected (1 vs 5; P = .01).

^†With reference to Essen and Marburg.